Syntekabio and Enamine partner for AI-based drug development

Syntekabio has entered a partnership with Enamine for supply, synthesis of compounds and synthetic drug development.

Sep 4, 2024 - 04:00

Syntekabio and Enamine partner for AI-based drug development

Syntekabio has entered a partnership with Enamine for supply, synthesis of compounds and synthetic drug development.

Read the original article

Tags:

Previous Article

Why the Importer of Record (IoR) is vital in the clinical supply chain

ESC 2024: Beta blocker treatment paradigm shifts for myocardial infarction

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Capstan secures $175m Series B funds for CAR-T therapy

Capstan secures $175m Series B funds for CAR-T therapy

Mar 22, 2024

STAT+: Pharmalittle: Biden pharma patent proposal spurs fears; Klobuchar questions company behind price spike of lead poisoning antidote

STAT+: Pharmalittle: Biden pharma patent proposal spurs...

Dec 9, 2023

Takeda and BMC partner to decarbonise US healthcare sector

Takeda and BMC partner to decarbonise US healthcare sector

Oct 26, 2024